Tyrosine Kinase Inhibitors 

  Products    Products    Diseases    News 


«12...278279280281282283284285286287288...49864987»
  • ||||||||||  Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
    Journal, Gene Signature, IO Companion diagnostic, PD(L)-1 Biomarker, IO biomarker, PD(L)-1 companion diagnostic:  Development of mutated ?-catenin gene signature to identify CTNNB1 mutations from whole and spatial transcriptomic data in patients with HCC. (Pubmed Central) -  Nov 25, 2024   
    We have developed a molecular signature that could serve as a companion diagnostic and uses bulk or spatial transcriptomic data to identify a unique subclass of liver tumors. This subgroup of liver cancer patients derive limited benefit from the current standard of care and are expected to benefit from specialized directed therapies that are on the horizon.
  • ||||||||||  Jakafi (ruxolitinib) / Incyte, Opzelura (ruxolitinib cream) / Incyte
    Journal:  Case series of topical 1.5% ruxolitinib cream for pediatric vitiligo. (Pubmed Central) -  Nov 25, 2024   
    This subgroup of liver cancer patients derive limited benefit from the current standard of care and are expected to benefit from specialized directed therapies that are on the horizon. No abstract available
  • ||||||||||  Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
    Journal:  A rapid progression from classical mantle cell lymphoma to a blastoid variant. (Pubmed Central) -  Nov 25, 2024   
    Despite subsequent intensive treatment, including high-dose cytarabine (Cytarabine), rituximab, and intrathecal methotrexate (Methotrexate), the patient's disease continued to advance, resulting in death. This case underscores the aggressive nature of blastoid MCL, its poor prognosis despite current therapeutic strategies, and highlights the need for individualized treatment approaches and CNS prophylaxis.
  • ||||||||||  Rituxan (rituximab) / Roche, Calquence (acalabrutinib) / AstraZeneca
    Trial primary completion date:  Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL (clinicaltrials.gov) -  Nov 25, 2024   
    P2,  N=35, Active, not recruiting, 
    Trial completion date: Aug 2025 --> May 2026 | Trial primary completion date: Dec 2024 --> Oct 2025 Trial primary completion date: Sep 2024 --> Feb 2025
  • ||||||||||  Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Metastases:  LEADER: Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma (clinicaltrials.gov) -  Nov 25, 2024   
    P1/2,  N=30, Active, not recruiting, 
    Trial primary completion date: Sep 2024 --> Feb 2025 Trial completion date: Jun 2023 --> Dec 2024
  • ||||||||||  everolimus / Generic mfg., sirolimus / Generic mfg., cyclosporine / Generic mfg.
    Journal:  The measurement of immunosuppressive drugs bymass spectrometry and immunoassay in a SouthAfrican transplant setting. (Pubmed Central) -  Nov 25, 2024   
    The cyclosporine ECLIA yielded results comparable to LC-MS/MS while poorly comparable results were obtained for everolimus and sirolimus, which may be explained by ISD metabolite cross-reactivity, amongst other factors. The poor comparability, although not unique, is noteworthy and the clinical consequences of these differences require further investigation.
  • ||||||||||  Review, Journal:  The evolution of BRAF-targeted therapies in melanoma: overcoming hurdles and unleashing novel strategies. (Pubmed Central) -  Nov 25, 2024   
    The review also delves into the role of advanced therapeutic tools, such as mRNA vaccines and CRISPR-Cas9, in revolutionizing personalized oncology by targeting specific genetic mutations and enhancing immune responses against melanoma. The ongoing synergy between advancing research, targeted interventions, strategic treatment combinations, and cost-effectiveness evaluations offers a promising pathway to elevate patient outcomes in the persistent battle against melanoma significantly.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
    Journal, HEOR, Cost-effectiveness, Cost effectiveness, Metastases:  First-Line Camrelizumab Plus Rivoceranib in Advanced Hepatocellular Carcinoma: A China-Based Cost-Effectiveness Analysis. (Pubmed Central) -  Nov 25, 2024   
    The results of the subgroup analysis demonstrated camrelizumab plus rivoceranib was the most cost-effective in the subgroup with albumin-bilirubin grade 2. At a willingness-to-pay threshold of US$36?780/QALY, camrelizumab plus rivoceranib is likely to be a cost-effective option compared with sorafenib as first-line treatment for advanced hepatocellular carcinoma in China.
  • ||||||||||  Trial completion date, Trial primary completion date:  Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction (clinicaltrials.gov) -  Nov 25, 2024   
    P2,  N=70, Recruiting, 
    At a willingness-to-pay threshold of US$36?780/QALY, camrelizumab plus rivoceranib is likely to be a cost-effective option compared with sorafenib as first-line treatment for advanced hepatocellular carcinoma in China. Trial completion date: Nov 2024 --> Nov 2026 | Trial primary completion date: Nov 2024 --> Nov 2025
  • ||||||||||  tofacitinib / Generic mfg.
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Checkpoint inhibition:  Tofacitinib for the Treatment of Refractory Immune-related Colitis from Checkpoint Inhibitor Therapy- TRICK Study (clinicaltrials.gov) -  Nov 25, 2024   
    P2,  N=2, Terminated, 
    N=92 --> 358 | Trial completion date: Jun 2025 --> Apr 2027 | Trial primary completion date: Apr 2025 --> Nov 2025 N=10 --> 2 | Trial completion date: Sep 2025 --> Jan 2024 | Recruiting --> Terminated | Trial primary completion date: May 2025 --> Jan 2024; sponsor decision, due to low recruitment rate
  • ||||||||||  Tagrisso (osimertinib) / AstraZeneca
    Trial completion, HEOR, Real-world evidence:  KOREA-PLUS: Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy - PLUS (clinicaltrials.gov) -  Nov 25, 2024   
    P=N/A,  N=923, Completed, 
    N=10 --> 2 | Trial completion date: Sep 2025 --> Jan 2024 | Recruiting --> Terminated | Trial primary completion date: May 2025 --> Jan 2024; sponsor decision, due to low recruitment rate Recruiting --> Completed
  • ||||||||||  New trial, Adverse events, IO biomarker:  The Effect of Serum Ferritin in irAE (clinicaltrials.gov) -  Nov 25, 2024   
    P=N/A,  N=1500, Recruiting, 
  • ||||||||||  Eylea (aflibercept intravitreal) / Regeneron
    Trial completion date, Trial primary completion date:  Mean Visual Acuity Changes Following Five Injections of Aflibercept (clinicaltrials.gov) -  Nov 24, 2024   
    P=N/A,  N=48, Active, not recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
  • ||||||||||  anvatabart opadotin (JNJ-0683) / J&J
    Trial completion date, Trial initiation date, Trial primary completion date:  ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer (clinicaltrials.gov) -  Nov 24, 2024   
    P2,  N=36, Not yet recruiting, 
    Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Sep 2024 --> Sep 2025 Trial completion date: Feb 2028 --> Jun 2028 | Initiation date: Oct 2024 --> Jan 2025 | Trial primary completion date: Feb 2028 --> Jun 2028
  • ||||||||||  levofloxacin / Generic mfg., rifampicin / Generic mfg., doxycycline / Generic mfg.
    Review, Journal:  Coxiella burnetii caused lumbar infection: A case report and literature review. (Pubmed Central) -  Nov 24, 2024   
    This case highlights mNGS as a valuable tool for diagnosing rare infections, especially in patients with a history of animal exposure. It underscores the importance of considering zoonotic infections and the need for combined antibiotic and surgical management in suspected cases.
  • ||||||||||  Imbruvica (ibrutinib) / AbbVie, J&J
    Review, Journal:  Advances in the treatment of mantle cell lymphoma with BTK inhibitors. (Pubmed Central) -  Nov 23, 2024   
    The first generation of BTK inhibitors, led by ibrutinib, have shown promising results in targeted treatment...This review summarizes the pathogenesis of MCL and targeted BTK inhibitors and provides an overview of the mutations that can lead to resistance to BTK inhibitors. The purpose of this article is to review the literature describing these selective therapies and provides perspectives for their further development.
  • ||||||||||  dasatinib / Generic mfg.
    Journal:  Applying molecular hybridization to design a new class of pyrazolo[3,4-d]pyrimidines as Src inhibitors active in hepatocellular carcinoma. (Pubmed Central) -  Nov 23, 2024   
    Starting from these data, we applied a molecular hybridization approach to combine the in-house pyrazolo[3,4-d]pyrimidine SI192 with the approved TK inhibitor (TKI) dasatinib, with the aim of identifying a new generation of Src inhibitors...The ADME profile suggested that 7e deserves further investigation as a promising TKI in cancer therapies. Finally, 7e's ability to inhibit HepG2 cell proliferation, elicit an irreversible cytotoxic effect, arrest cellular migration, and induce apoptotic-mediated cell death was assessed.
  • ||||||||||  ciprofloxacin oral / Generic mfg., rifampicin / Generic mfg., erythromycin / Generic mfg.
    Journal:  Second messenger c-di-AMP regulates multiple antibiotic sensitivity pathways in Mycobacterium smegmatis by discrete mechanisms. (Pubmed Central) -  Nov 23, 2024   
    We studied four antibiotics with different mechanisms of action: rifampicin, ciprofloxacin, erythromycin, and tobramycin and subsequently found that the level of drug sensitivity of the bacteria is directly proportional to the c-di-AMP concentration inside the cell. Further, we unraveled the underlying molecular mechanisms to delineate the specific genes and pathways regulated by c-di-AMP and hence result in differential drug sensitivity in M. smegmatis.
  • ||||||||||  rifampicin / Generic mfg.
    Journal, Monotherapy:  Examining effective monotherapy hypothesis for TB therapy failure and resistance emergence. (Pubmed Central) -  Nov 23, 2024   
    BACKGROUNDWe tested the hypothesis that because of the different metabolic states of Mycobacterium tuberculosis (Mtb) in lesions, drugs in combination therapy often act effectively as monotherapy, leading to therapy failure and resistance emergence.METHODSBactericidal and sterilizing activity studies were performed in the hollow fiber system of TB (HFS-TB) using the human equivalent dose of isoniazid (INH) 300 mg/day, rifampin (RIF) 600 mg/day, and pyrazinamide (PZA) 1.5 g/day either as monotherapy, two-, and three-drug combination for 28 days...RIF and INH-resistant subpopulations did not increase despite premixing the inoculum with isogenic-resistant strains.CONCLUSIONEffective monotherapy arising from the selectivity of antibiotics against special Mtb sub-populations may not be the primary mechanism of resistance emergence. Different metabolic populations of Mtb were killed by more than one drug and were not under monotherapy when combination therapy was administered..
  • ||||||||||  imatinib / Generic mfg.
    Journal, Stroma:  Intratumoral Bacteria are Uncommon in Gastrointestinal Stromal Tumor. (Pubmed Central) -  Nov 23, 2024   
    Different metabolic populations of Mtb were killed by more than one drug and were not under monotherapy when combination therapy was administered.. GISTs generally lack substantial bacteria, except in some cases when the tumor disrupts the mucosa.
  • ||||||||||  Tepezza (teprotumumab-trbw) / Roche, Amgen
    Review, Journal:  Advances of IGF-1R inhibitors in Graves' ophthalmopathy. (Pubmed Central) -  Nov 23, 2024   
    Clinical trials have shown that teprotumumab reduces proptosis better than placebo, and may be beneficial for patients with worsening disease after steroid cessation. In this review, we discuss the role and prospects of IGF-1R inhibitors in thyroid-associated ophthalmopathy.
  • ||||||||||  rifampicin / Generic mfg.
    Journal:  Urine-Xpert Ultra for the diagnosis of tuberculosis in people living with HIV: a prospective, multicentre, diagnostic accuracy study. (Pubmed Central) -  Nov 23, 2024   
    P=N/A
    Urine-Xpert Ultra (Cepheid) could improve time to diagnosis of tuberculosis disease and rifampicin resistance...In inpatient settings where both AlereLAM and Urine-Xpert Ultra are possible, both should be offered to support rapid diagnosis and treatment. Global Health Innovative Technology Fund, KfW Development Bank, Commonwealth of Australia represented by the Department of Foreign Affairs and Trade, and the Netherlands Enterprise Agency.
  • ||||||||||  Tyvyt (sintilimab) / Eli Lilly
    Biomarker, P2 data, Journal, PD(L)-1 Biomarker, IO biomarker:  Sintilimab plus decitabine for higher-risk treatment-na (Pubmed Central) -  Nov 23, 2024   
    P=N/A
    The combination of sintilimab and decitabine shows promise efficacy for higher-risk MDS, with a favorable safety profile. The potential predictive value of T cell exhaustion biomarkers might help screen the possible benefiting population.